Alzheimers Disease
NEJM 362:329-344, Querfurth,H.W. &LaFerla,F.M., 2010
Age, Neuropathology, and Dementia
NEJM 360:2302-2309, Savva,G.M.,et al, 2009
Neuropathologic Features of Amnestic Mild Cognitive Impairment
Arch Neurol 63:665-672,645, Petersen,R.C.,et al, 2006
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
NEJM 355:2652-2663, Small,G.W.,et al, 2006
A 10-Item Smell Identification Scale Related to Risk for Alzheimers Disease
Ann Neurol 58:155-160, Taberr,M.H.,et al, 2005
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Apolipoprotein E, Dementia, and Cortical Deposition of B-Amyloid Protein
NEJM 333:1242-1247, 12831995., Polvikoski,T.,et al, 1995
Regional Distrib of Neurofibrillary Tangles & Senile Plaques in Cerebral Cortex of Very Old Pts
Arch Neurol 52:1150-1159, Gioannakopoulos,P.,et al, 1995
Alzheimer's-Disease-Like Changes in Tau Protein Processing:Assoc with Aluminium Accum in Brains of Dialysis Pts
Lancet 343:993-997, 9891994., Harrington,C.R.,et al, 1994
Clinical, Path, & Neurochem Changes in Dementia:Subgroup with Preserved Mental Status & Neocortical Plaques
Ann Neurol 23:138-144, Katzman,R.,et al, 1988
Dementia in Down's Syndrome:Cerebral Glucose Utilization, Neuropsychological Assessment, and Neuropathology
Neurol 38:938-942, Schapiro,M.B.,et al, 1988
Aluminium, Chemical Physiology and Alzheimer's Disease
Lancet 2:1008-1010, Birchall,J.D.&Chappell,J.S., 1988
Immunocytochemistry of Neurofibrillary Tangles in Dementia Pugilistica and Alzheimer's Disease:Evidence for Common Genesis
Lancet 2:1456-1458, Roberts,G.W., 1988
Brain Amyloid and Alzheimer Disease
Ann Int Med 109:41-54, Vinters,H.V.,et al, 1988
Alzheimer's Disease
NEJM 314:964-973, Katzman,R., 1986
Neuronal Pathology in the Nucleus Basalis & Associated Cell Groups in Senile Dementia of the Alzheimer's Type
Neurol 35:1089-1095, Saper,C.B.,et al, 1985
The Olfactory Bulbs in Alzheimer's Disease
JNNP 47:56-60, Esiri,M.M.&Wilcock,G.K., 1984
Dementia From Aluminum Pots
NEJM 303:164, Levick,S.E., 1980
Dementia in Parkinson Disease:A Neuropathologic Study
Neurol 29:1209-1214, Hakim,A.M.,et al, 1979
Huntington Disease Associated with Alzheimer Disease
Ann Neurol 3:545, McIntosh,G.C.,et al, 1978
Elevated Manganese Levels Associated with Dementia & Extrapyramidal Signs
Neurol 27:213, Banta,R.G.,et al, 1977
Alzheimers Disease with Abnormal CSF Flow
Neurol 23:1058, Sohn,R.S.,et al, 1973
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Real-World Evidence of Brexpiprazole Use and 6-Month Mortality, Hospitalization, and Emergency Department Visits Among Persons with Dementia
Neurol 105: e213717, Zissimopoulos, J.,et al, 2025
Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Tau Positron Emission Tomography for Predicting Dementia in Individuals with Mild Cognitive Impairment
JAMA Neurol 81:845-856, Groot,C.,et al, 2024
Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Revised Criteria for Diagnosis and Staging of Alzheimers Disease: Alzheimers Association Workgroup
Alzheimers Dement 20:5143-5169, Jack,Jr.,C.R.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Cognitive and Clinical Characteristics of Patients with Limbic-Predominant Age-Related TDP-43 Encephalopathy
Neurol 100:e2027-e2035, Pagnotti,R.M.B.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Toward Gerineuropalliative Care for Patients with Dementia
NEJM 389:775-778, Harrison,K.L.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients with Early Alzheimer Disease
Neurol 98:e968-e977, Whittington, M.D.,et al, 2022
An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
The Effects of Long-Term Medication Use in Alzheimer Disease
Neurol 96:e2247-e2250, Karceski, S., 2021
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Application of Deep Learning to Predict Standardized Uptake Value Ratio and Amyloid Status on 18F-Florbetapir PET Using ADNI Data
AJNR 41:980-986, Reith, F.,et al, 2020
Debate Sparks Over LATE, a Recently Recognized Dementia
JAMA 322:914-916, Abbasi, J., 2019
Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Outcomes after Diagnosis of Mild Cognitive Impairment in a Large Autopsy Series
Ann Neurol 81:549-559, Abner, E.L.,et al, 2017